TMO Long Call Strategy
TMO (Thermo Fisher Scientific Inc.), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NYSE.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD.
TMO (Thermo Fisher Scientific Inc.) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $165.75B, a trailing P/E of 24.19, a beta of 0.88 versus the broader market, a 52-week range of 385.46-643.99, average daily share volume of 2.1M, a public-listing history dating back to 1980, approximately 125K full-time employees. These structural characteristics shape how TMO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.88 places TMO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. TMO pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a long call on TMO?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current TMO snapshot
As of May 15, 2026, spot at $437.94, ATM IV 30.92%, IV rank 45.02%, expected move 8.87%. The long call on TMO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this long call structure on TMO specifically: TMO IV at 30.92% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 8.87% (roughly $38.83 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated TMO expiries trade a higher absolute premium for lower per-day decay. Position sizing on TMO should anchor to the underlying notional of $437.94 per share and to the trader's directional view on TMO stock.
TMO long call setup
The TMO long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With TMO near $437.94, the first option leg uses a $440.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed TMO chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 TMO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $440.00 | $14.85 |
TMO long call risk and reward
- Net Premium / Debit
- -$1,485.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$1,485.00
- Breakeven(s)
- $454.85
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
TMO long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on TMO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$1,485.00 |
| $96.84 | -77.9% | -$1,485.00 |
| $193.67 | -55.8% | -$1,485.00 |
| $290.50 | -33.7% | -$1,485.00 |
| $387.33 | -11.6% | -$1,485.00 |
| $484.16 | +10.6% | +$2,930.92 |
| $580.99 | +32.7% | +$12,613.91 |
| $677.82 | +54.8% | +$22,296.89 |
| $774.65 | +76.9% | +$31,979.88 |
| $871.48 | +99.0% | +$41,662.86 |
When traders use long call on TMO
Long calls on TMO express a bullish thesis with defined risk; traders use them ahead of TMO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
TMO thesis for this long call
The market-implied 1-standard-deviation range for TMO extends from approximately $399.11 on the downside to $476.77 on the upside. A TMO long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current TMO IV rank near 45.02% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on TMO should anchor more to the directional view and the expected-move geometry. As a Healthcare name, TMO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to TMO-specific events.
TMO long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. TMO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move TMO alongside the broader basket even when TMO-specific fundamentals are unchanged. Long-premium structures like a long call on TMO are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current TMO chain quotes before placing a trade.
Frequently asked questions
- What is a long call on TMO?
- A long call on TMO is the long call strategy applied to TMO (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With TMO stock trading near $437.94, the strikes shown on this page are snapped to the nearest listed TMO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are TMO long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the TMO long call priced from the end-of-day chain at a 30-day expiry (ATM IV 30.92%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,485.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a TMO long call?
- The breakeven for the TMO long call priced on this page is roughly $454.85 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TMO market-implied 1-standard-deviation expected move is approximately 8.87%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on TMO?
- Long calls on TMO express a bullish thesis with defined risk; traders use them ahead of TMO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current TMO implied volatility affect this long call?
- TMO ATM IV is at 30.92% with IV rank near 45.02%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.